Beijing Tiantan Biological Products (600161) H1 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached RMB 2.84 billion, up 5.59% year-over-year, with net profit attributable to shareholders at RMB 726 million, up 28.12% year-over-year.

• Gross margin improved to 55.66%, up 7.18 percentage points year-over-year, driven by higher product prices and cost control.

• The company maintained its leading position in China's plasma products industry, with 80 operating plasma stations and a 20% market share in plasma collection.

• R&D investment and pipeline expansion continued, with new product approvals and clinical progress in key biologics.

Financial highlights

• Operating income: RMB 2.84 billion, up 5.59% year-over-year.

• Net profit attributable to shareholders: RMB 726 million, up 28.12% year-over-year.

• Operating profit reached RMB 1.19 billion, a 27.49% increase year-over-year.

• Basic and diluted EPS: RMB 0.37, up 28.12% year-over-year.

• Gross margin: 55.66%, up 7.18 percentage points year-over-year.

Outlook and guidance

• The company aims to further expand plasma collection and production capacity, with new facilities in Yunnan and Lanzhou progressing.

• Focus remains on R&D, digital transformation, and international market expansion.

• Management expects continued growth in revenue and profit, supported by product mix optimization and cost control.